Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in 2024.

The post Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue appeared first on Investor’s Business Daily.